These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24530341)

  • 1. Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer.
    Friedersdorff F; Manus P; Miller K; Lein M; Jung K; Stephan C
    Clin Biochem; 2014 Jul; 47(10-11):916-20. PubMed ID: 24530341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
    Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
    Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
    BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
    Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
    Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
    Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
    Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.
    Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G
    Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
    PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
    Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
    BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
    Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Gleason score with PSA Values and Serum Testosterone Levels Measured Prior To Prostate Biopsy.
    Temel MC; Ediz C; Akan S; Ozer E; Yilmaz O
    J Coll Physicians Surg Pak; 2020 Apr; 30(4):399-402. PubMed ID: 32513360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
    Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
    Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
    J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?
    Shepherd L; Borges ÁH; Ravn L; Harvey R; Bower M; Grulich A; Silverberg M; Kronborg G; Galli M; Kirk O; Lundgren J; Mocroft A;
    Antivir Ther; 2016; 21(6):529-534. PubMed ID: 26823399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.